[61F4-61F4];[61F6-61F6];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
61F4;61F6
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(3L)ED207.
The presence of P+PBac{XP5.RB3}BSC250 was verified using the PCR methods and primers described in FBrf0175003 with the substitution of the primer 5'-CCAATGCGTTTATTTCAGGTCACG-3' for the RB3' plus or RB3' minus primer in the Hybrid PCR protocol in the Supplementary Methods.
Exelixis, Inc. determined the insertion site of P{XP}d01193 to be at Release 3 genomic coordinate 1315105 on chromosome arm 3L. The Gene Disruption project determined the insertion site of P{XP}d01193 to be at Release 3 genomic coordinate 1315208 on arm 3L. This corresponds to 61F6 on the Release 3 and 4 genome maps. The predicted position of PBac{RB}CG9134e00088 on the Release 4 genome map is 61F4. Consequently, the cytological breakpoints of Df(3L)BSC250 are predicted to be 61F4;61F6.